Compound 1 was subjected to a panel

Compound 1 was subjected to a panel of in vitro bioassays,
including cytotoxic, immunomodulatory, antiglycation, antioxidant
and enzyme inhibition assays. It showed significant in vitro
cytotoxicity to every cell line tested, including human cervical
cancer (HeLa), prostate cancer (PC-3) and normal mouse fibroblast
(3T3) cell lines (Table 2). The cytotoxicity (IC50) of1 against HeLa cell
line (IC50 = 6.87  0.32) was about half of the standard drug,
doxorubicin (IC50 = 3.10  0.20). Compound 1 was found to be inactive
in immunomodulatory, antiglycation and antioxidant assays. It
exhibited no significant inhibition for carbonic anhydrase II, achymotrypsin, urease, b-glucuronidase and phosphodiesterase. This
indicated specificity ofcompound 1 for highly proliferating cancercells.

ผลลัพธ์ (อังกฤษ) 2:

Compound 1 was subjected to a Panel of bioassays in vitro,
including cytotoxic, immunomodulatory, Antiglycation, antioxidant
and enzyme inhibition assays. Showed significant in vitro
cytotoxicity to Cell Every line tested, including Human cervical
Cancer (HeLa), prostate Cancer (PC-3) and Normal Mouse fibroblast
(3T3) Cell Lines (Table 2). The cytotoxicity (IC50) against HeLa Cell Of1
line (IC50 = 6.87? 12:32 a.m.) was About Half of the Drug standard,
doxorubicin (IC50 = 3:10? twelve twenty a.m.). Compound 1 was Found to be inactive
in immunomodulatory, and antioxidant assays Antiglycation. It
exhibited no significant inhibition carbonic anhydrase II for, Achymotrypsin, urease, B-glucuronidase and phosphodiesterase. This
specificity Indicated Ofcompound 1 for highly proliferating Cancercells.